CN112292401A - 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 - Google Patents

丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 Download PDF

Info

Publication number
CN112292401A
CN112292401A CN201980017414.6A CN201980017414A CN112292401A CN 112292401 A CN112292401 A CN 112292401A CN 201980017414 A CN201980017414 A CN 201980017414A CN 112292401 A CN112292401 A CN 112292401A
Authority
CN
China
Prior art keywords
seq
sequence
antibody
spike
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980017414.6A
Other languages
English (en)
Chinese (zh)
Inventor
陆选永
F·Y·陆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingkai Biotechnology Co ltd
Original Assignee
Yingkai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yingkai Biotechnology Co ltd filed Critical Yingkai Biotechnology Co ltd
Priority to CN202510180099.6A priority Critical patent/CN120005029A/zh
Publication of CN112292401A publication Critical patent/CN112292401A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980017414.6A 2018-03-06 2019-03-06 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 Pending CN112292401A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510180099.6A CN120005029A (zh) 2018-03-06 2019-03-06 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862639345P 2018-03-06 2018-03-06
US62/639,345 2018-03-06
US201862639850P 2018-03-07 2018-03-07
US62/639,850 2018-03-07
PCT/US2019/020999 WO2019173503A2 (en) 2018-03-06 2019-03-06 Serine protease inhibitor kazal (spik) compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510180099.6A Division CN120005029A (zh) 2018-03-06 2019-03-06 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法

Publications (1)

Publication Number Publication Date
CN112292401A true CN112292401A (zh) 2021-01-29

Family

ID=65818672

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980017414.6A Pending CN112292401A (zh) 2018-03-06 2019-03-06 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
CN202510180099.6A Pending CN120005029A (zh) 2018-03-06 2019-03-06 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510180099.6A Pending CN120005029A (zh) 2018-03-06 2019-03-06 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法

Country Status (6)

Country Link
US (2) US12180301B2 (https=)
EP (1) EP3762426A2 (https=)
JP (2) JP7328261B2 (https=)
CN (2) CN112292401A (https=)
CA (1) CA3093295A1 (https=)
WO (1) WO2019173503A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292401A (zh) 2018-03-06 2021-01-29 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
EP3996816A1 (en) * 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
WO2021050217A1 (en) 2019-09-11 2021-03-18 Imcare Biotech, Llc. Epitopes of anti-serine protease inhibitor kazal (spik) antibodies
EP4211468A4 (en) * 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011102999A2 (en) * 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
US20130280255A1 (en) * 2005-09-08 2013-10-24 Xuanyong Lu Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
US20140308657A1 (en) * 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies
CN105968209A (zh) * 2011-04-19 2016-09-28 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
CA2703140A1 (en) 2007-10-25 2009-04-30 Viventia Biotech Inc. Antibodies against a cancer-associated epitope of variant hnrnpg and uses thereof
MX2011010265A (es) 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
WO2014127200A1 (en) 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP4219559A3 (en) * 2017-12-22 2023-10-18 Jounce Therapeutics, Inc. Antibodies for lilrb2
CN112292401A (zh) 2018-03-06 2021-01-29 英凯尔生物科技有限责任公司 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法
CN109678950B (zh) 2019-01-08 2022-05-10 灏灵赛奥（天津）生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
CN109776679B (zh) * 2019-01-08 2022-06-17 灏灵赛奥（天津）生物科技有限公司 一种丝氨酸蛋白酶抑制因子spink1的抗体、其制备方法和应用
EP3996816A1 (en) 2019-07-08 2022-05-18 Imcare Biotech, LLC Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
MX2022012752A (es) * 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280255A1 (en) * 2005-09-08 2013-10-24 Xuanyong Lu Identification of modulators of serine protease inhibitor kazal and their use as anti-cancer and anti-viral agents
WO2011102999A2 (en) * 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
US20140308657A1 (en) * 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies
CN105968209A (zh) * 2011-04-19 2016-09-28 美国政府(由卫生和人类服务部的部长所代表) 对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘俊秋, 时成波, 姜明守, 罗贵民, 闫岗林, 沈家骢: "化学修饰抗体增加模拟酶的GPX活性", 中国生物化学与分子生物学报, no. 03 *
李秋 , 雷正明: "肝缺血再灌注损伤的药物预处理(文献综述)", 国外医学.外科学分册, no. 04 *

Also Published As

Publication number Publication date
CA3093295A1 (en) 2019-09-12
WO2019173503A2 (en) 2019-09-12
JP2021515597A (ja) 2021-06-24
US20250353927A1 (en) 2025-11-20
EP3762426A2 (en) 2021-01-13
US12180301B2 (en) 2024-12-31
CN120005029A (zh) 2025-05-16
JP7539536B2 (ja) 2024-08-23
US20210253734A1 (en) 2021-08-19
JP2023166377A (ja) 2023-11-21
JP7328261B2 (ja) 2023-08-16
WO2019173503A3 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP7539536B2 (ja) セリンプロテアーゼ阻害剤カザル（ｓｐｉｋ）組成物および方法
CN106661110B (zh) 抗muc1抗体或其抗原结合片段及其用途
JP6180931B2 (ja) 癌の診断および／または予後のための新規な抗体
JP6586648B2 (ja) 抗プログルカゴン抗体
WO2013063186A2 (en) Monoclonal antibodies and methods of use
TW200823293A (en) Novel anti-Notch3 antibodies and their use in the detection and diagnosis of disease
US12377162B2 (en) Anti-serine protease inhibitor kazal (SPIK) antibodies, immunoconjugates, and methods of use
CN108700586A (zh) 用于评估癌症发生的风险的组合物和方法
CA2605745A1 (en) Cancer specific pcna isoform binding antibodies and uses thereof
JP6977105B2 (ja) Ｉｇｆ−１ｒ抗体および癌の診断のためのその使用
JP2026012693A (ja) 抗セリンプロテアーゼインヒビターｋａｚａｌ（ｓｐｉｋ）抗体のエピトープ
EP2970491A1 (en) Monoclonal antibodies to egfr, and uses therefor
CN117242093A (zh) 免疫组织化学方法和kir3dl2特异性试剂
WO2023223796A1 (ja) コリバクチン産生大腸菌結合性抗体
CN116547301A (zh) 使用抗体进行的细胞表面mica和micb检测
KR20260016944A (ko) 항-클라우딘18.2 항체 및 이의 제조 및 사용 방법
TW202521156A (zh) 重組抗體、包含其之套組以及其於診斷癌症之用途
JP2022501062A (ja) Ｅｐｎ１を標的とする抗体
HK1262633B (zh) 用於评估癌症发生的风险的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination